NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs

Core Insights - NervGen Pharma Corp. has appointed Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as Senior Vice President, Patient Advocacy and Clinical Affairs, to strengthen its leadership team during a critical execution phase [1][2] Leadership Appointments - Shamim Ruff brings over 30 years of regulatory affairs experience, having previously held leadership roles at Stoke Therapeutics and Sarepta Therapeutics, and will oversee NervGen's regulatory strategy [2][3] - Christine McSherry has more than 30 years of experience in patient advocacy and clinical development, previously co-founding Casimir, a clinical research organization, and will ensure the voice of the spinal cord injury (SCI) community is central to NervGen's clinical strategy [3][4] Product Development - NVG-291, NervGen's lead therapeutic candidate, is a neuroreparative peptide that has shown promising clinical data in the Phase 1b/2a CONNECT SCI Study, indicating evidence of nervous system repair [3][6] - The CONNECT SCI Study is ongoing for individuals with subacute SCI, and preparations for a Phase 3 clinical trial in chronic SCI are underway [6] Regulatory Designations - NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency (EMA) for the treatment of SCI, highlighting its potential as a first pharmacologic treatment for this condition [6]